DYSLIPIDEMIA IN PATIENTS WITH CHRONIC KIDNEY DISEASE
Abstract
Summury. Data about lipid disorders at different stages of chronic kidney disease (CKD), including those on dialysis are presented in the review. The possible influence of dyslipidemia on the progression of CKD, as well as the onset and progression of cardiovascular complications in patients with CKD are discussed. The questions of lipid-lowering therapy use, including statins, in patients with CKD on dialysis and predialysis, are disclosed.
Downloads
References
A controlled, prospective study of the effects of atorvas- tatin on proteinuria and progression of kidney disease / S. Bianchi, R. Bigazzi, A. Caiazza, V. M. Campese // Am. J. Kidney Dis. - 2003. - Vol. 41. - P. 565-570.
Add-on and withdrawal effect of pravastatin on proteinuria in hypertensive patients treated with AT receptor blockers / T. M. Lee, M. S. Lin, C. H. Tsai, N. C.Chang // Kidney Int. - 2005. - Vol. 68. - P. 779-787.
Analysis of glomerulosclerosis and atherosclerosis in lecithin cholesterol acyltransferase-deficient mice / G. Lambert, N. Sakai, B. L. Vaisman [et al.] // J. Biol. Chem. - 2001. - Vol. 276. - P. 15090-15098.
Association between cholesterol level and mortality in dialysis patients: role of inflammation and malnutrition / Y. Liu, J. Coresh, J. A. Eustace [et al.] // JAMA. - 2004. - Vol. 291. - Р. 451-459.
Atorvastatin and low-density lipoprotein cholesterol in type 2 diabetes mellitus patients on hemodialysis / W. März, B. Genser, C. Drechsler [et al.] // Clin. J. Am. Soc. Nephrol. - 2011. - Vol. 6. - P. 1316-1325.
Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis / C. Wanner, V. Krane, W. März [et al.] // N. Engl. J. Med. - 2005. - Vol. 353. - Р. 238-248.
Benefits and harms of statin therapy for persons with chronic kidney disease: a systematic review and metaanalysis / S. C. Palmer, J. C. Craig, S. D. Navaneethan [et al.] // Ann. Intern. Med. - 2012. - Vol. 157. - P. 263-275.
Biomarkers of inflammation and progression of chronic kidney disease / M. Tonelli, F. Sacks, M. Pfeffer [et al]. // Kidney Int. - 2005. -Vol. 68. - P. 237-245.
Campese V. M. HMG-CoA reductase inhibitors and renal function / V. M. Campese, J. Park // Clin. J. Am. Soc. Nephrol. - 2007. -Vol. 2. - P. 1100-1103.
Cholesterol and the risk of renal dysfunction in apparently healthy men / E. S. Schaeffner, T. Kurth, G. C. Curhan [et al.] // J. Am. Soc. Nephrol. – 2003. – Vol. 14. - P. 2084-2091.
Chronic kidney disease and mortality risk: a systematic review / M. Tonelli, N. Wiebe, B. Culleton [et al.] // J. Am. Soc. Nephrol. - 2006. - Vol. 17. - P. 2034-2047.
Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization / A. S.Go, G. M. Chertow, D. Fan [et al.] // N. Engl. J. Med. - 2004. - Vol. 351. - P. 1296-1305.
Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: a pooled analysis of community-based studies / D. E.Weiner, H. Tighiouart, M. G. Amin [et al.] // J. Am. Soc. Nephrol. - 2004. - Vol. 15. - P. 1307-1315.
Drüke T. B. Atherosclerosis in CKD: differences from the general population / T. B. Drüke, Z. A. Massy // Nat. Rev. Nephrol. - 2010. - Vol. 6. - P. 723-735.
Dyslipidaemia as predictor of progressive renal failure and the impact of treatment with atorvastatin / R. C. Ozsoy, W. A. van der Steeg, J. J. Kastelei [et al.] // Nephrol. Dial. Transplant. - 2007. - Vol. 22. - P. 1578-1586.
Effect of intensive lipid lowering with atorvasta- tin on renal function in patients with coronary heart disease: the Treating to New Targets (TNT) study / J. Shepherd, J. J. Kastelein, V. Bittner [et al.] // Clin. J. Am. Soc. Nephrol. - 2007. - Vol. 2. -P. 1131-1139.
Effect of pravastatin on loss of renal function in people with moderate chronic renal insufficiency and cardiovascular disease / M. Tonelli, L. Moyé, F. M. Sacks [et al.] // J. Am. Soc. Nephrol. - 2003. - Vol. 14. - P. 1605-1613.
Effect of pravastatin on rate of kidney function loss in people with or at risk for coronary disease / M. Tonelli, C. Isles, T. Craven [et al.] // Circulation - 2005. - Vol. 112. - P. 171-178.
Effect of statin therapy on cardiovascular and renal outcomes in patients with chronic kidney disease: a systematic review and meta-analysis / W. Hou, J Lv, V. Perkovic [et al.] // Eur. Heart. J. - 2013. - Vol. 34. - P. 1807-1817.
Effects of add-on fluvastatin therapy in patients with chronic proteinuric nephropathy on dual renin-angiotensin system blockade: the ESPLANADE trial / P. Ruggenenti, A. Perna, M. Tonelli [et al.] // Clin. J. Am. Soc. Nephrol. - 2010. - Vol. 5. - P. 1928-1938.
Effects of hypertension and dyslipidemia on the decline in renal function / M. Manttari, E. Tiula, T. Alikoski, V. Manninen // Hypertension. - 1995. - Vol. 26. - P. 670-675.
Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials / G. F. Strippoli, S. D. Navaneethan,
D. W. Johnson [et al.] // BMJ. - 2008. - Vol. 336. - P. 645-651.
Effect of pravastatin on loss of renal function in people with moderate chronic renal insufficiency and cardiovascular disease / M. Tonelli, L. Moyé, F. M. Sacks [et al.] // J. Am. Soc. Nephrol. - 2003. - Vol. 14. - P. 1605-1619.
Effect of pravastatin on rate of kidney function loss in people with or at risk for coronary disease / M. Tonelli, C. Isles, T. Craven [et al.] // Circulation. - 2005. - Vol. 112. - P. 171-182.
Excerpts from the United States Renal Data System 2007 annual data report / A. J. Collins [et al.] // Am. J. Kidney Dis. - 2008. - Vol. 51, Suppl. 1. - P.1-320.
Foley R. N. Clinical epidemiology of cardiovascular disease in chronic renal disease / R. N. Foley, P.S. Parfrey, M. J. Sarnak // Am. J. Kidney. Dis. - 1998. - Vol. 32, Suppl. 3. - P. 112-119.
Gemfibrozil for secondary prevention of cardiovascular events in mild to moderate chronic renal insufficiency / M. Tonelli, D. Collins, S. Robins [et al.] // Kidney Int. - 2004. - Vol. 66. - P. 1123-1130.
HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis / S. D. Navaneethan, F. Pansini, V. Perkovic [et al.] // Cochrane Database Syst. Rev. - 2009. - Vol. 15 (2). - CD007784.
Hyperlipidemia aggravates renal disease in B6.ROP Os/+ mice / A. S. Mühlfeld, M. W. Spencer, K. L. Hudkins [et al.] // Kidney Int. - 2004. - Vol. 66. - P. 1393-1399.
Hypertriglyceridemia and lowered apolipoprotein C-II/C-III ratio in uremia: effect of a fibric acid, clino- fibrate / Y. Nishizawa, T. Shoji, H. Nishitani [et al.] // Kidney Int. - 1993. - Vol. 44. - P. 1352-1359.
Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study / J. Shepherd, J. J. Kastelein, V. Bittner [et al.] // J. Am. Coll. Cardiol. - 2008. - Vol. 51. - P. 1448-1454.
K/DOQI Clinical practice guidelines for management of dyslipidemias in patients with kidney disease // Am. J. Kidney Dis. - 2003. - Vol. 41, Suppl. 3. - P. 1-91.
Kaysen G. A. Lipid and lipoprotein metabolism in chronic kidney disease / G. A. Kaysen // J. Ren. Nutr. - 2009. - Vol. 19. - P. 73-77.
K/DOQI clinical practice guideline for diabetes and CKD: 2012 update // Am. J. Kidney Dis. - 2012. - Vol. 60 (5). - P. 850-886.
Keane W. F. Lipid abnormalities in patients with chronic kidney disease: implications for the pathophysiology of atherosclerosis / W. F. Keane, J. E. Tomassini,
D. R. Neff // J. Atheroscler. Thromb. - 2012. - Vol. 20. - P. 123-133.
Keane W. F. Lipids and progressive glomerulosclerosis. A model analogous to atherosclerosis / W. F. Keane, B. L. Kasiske, M. P. O’Donnell // Am. J. Nephrol. - 1988. - Vol. 8. - P. 261-271.
Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on kidney in cardiovascular disease, high blood pressure research, clinical cardiology, and epidemiology and prevention / M. J. Sarnak, A. S. Levey, A. C. Schoolwerth [et al.] // Circulation. - 2003. - Vol. 108. - P. 2154-2169.
Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease // // Kidney inter. - 2013. - Vol. 3, Suppl. - P. 1-150.
Kidney Disease: Improving Global Outcomes (KDIGO) Lipid Work Group. KDIGO Clinical Practice Guideline for Lipid Management in Chronic Kidney Disease. // Kidney inter. - 2013. - Vol.3, Suppl. - P. 259-305.
Lindeman R. D. Longitudinal studies on the rate of decline in renal function with age / R. D. Lindeman, J. Tobin, N. W. Shock // J. Am. Geriatr. Soc. - 1985. - Vol. 33. - P. 278-285.
Lipid-lowering therapy in persons with chronic kidney disease: a systematic review and meta-analysis / A. Upadhyay, A. Earley, J. L. Lamont [et al.] // Ann. Intern. Med. - 2012. - Vol. 157. - P. 251-262.
Lipoprotein abnormalities are associated with increased rate of progression of human chronic renal insufficiency / O. Samuelsson, H. Mulec, C. Knight- Gibson [et al.] // Nephrol. Dial. Transplant. - 1997. - Vol. 12. - P. 1908-1915.
Lipoprotein metabolism and lipid management in chronic kidney disease / B. C. Kwan, F. Kronenberg, S. Beddhu, A. K.Cheung // J. Am. Soc. Nephrol. - 2007. - Vol. 18. - P. 1246-1257.
Meta-analysis: the effect of statins on albuminuria / K. Douglas, P. G. O’Malley, J. L. Jackson // Ann. Intern. Med. - 2006. - Vol. 145. - P. 117-124.
MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial // Lancet. - 2002. - Vol. 360. - P. 7-22.
MRC/BHF Heart Protection Study of cholesterollowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial / R. Collins, J. Armitage, S. Parish [et al.] // Lancet. - 2003. - Vol. 361. - P. 2005-2016.
National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification / A. S. Levey, J. Coresh, E. Balk [et al.] // Ann. Intern. Med. - 2003. - Vol. 139. - P. 137-147.
Outcome and risk factors of ischemic heart disease in chronic uremia / P. S. Parfrey, R. N. Foley, J. D. Harnett [et al.] // Kidney Int. - 1996. - Vol. 49. - P. 1428-1434.
Plasma lipids and risk of developing renal dysfunction: the atherosclerosis risk in communities study / P. Muntner, J. Coresh, J. C. Smith [et al.] // Kidney Int. - 2000. - Vol. 58. - P. 293-301.
Pravastatin for secondary prevention of cardiovascular events in persons with mild chronic renal insufficiency / M. Tonelli, L. Moyé, F. M. Sacks [et al.] // Ann. Intern. Med. - 2003. - Vol. 138. - P. 98-104.
Prichard S. Risk factors for coronary artery disease in patients with renal failure / S. Prichard // Am. J. Med. Sci. - Vol. 325. - Vol. 209-213.
Progression of kidney disease in moderately hyper- cholesterolemic, hypertensive patients randomized to pravastatin versus usual care: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) / M. Rahman, C. Baimbridge, B. R. Davis [et al.] // Am. J. Kidney Dis. - 2008. - Vol. 52. - P. 412-424.
Rosuvastatin and cardiovascular events in patients undergoing hemodialysis / B. C.Fellstrom, A. G. Jardine, R. E. Schmieder [et al.] // N. Engl. J. Med. - 2009. - Vol. 36. - 1395-1407.
Sarnak M. J. Cardiovascular disease and chronic renal disease: a new paradigm / M. J. Sarnak, A. S. Levey // Am. J. Kidney Dis. – 2000. – Vol. 35, Suppl. 1. – P. 117-131.
Screening for monitoring, and treatment of chronic kidney disease stages 1 to 3: a systematic review for the U.S. Preventive Services Task Force and for an American College of Physicians Clinical Practice Guideline / H. A. Fink, A. Ishani, B. C. Taylor [et al.] // Ann. Intern. Med. – 2012. – Vol. 156. – P. 570-581.
Statins for improving renal outcomes: a meta-analysis / S. Sandhu, N. Wiebe, L. F. Fried, M. Tonelli // J. Am. Soc. Nephrol. – 2006. – Vol. 17. – P. 20062016.
The acute effect of atorvastatin on proteinuria in patients with chronic glomerulonephritis / R. C. Ozsoy, M. G. Koopman, J. J. Kastelein, L. Arisz // Clin. Nephrol. – 2005. – Vol. 63. – P. 245-249.
The effect of cholesterol reduction with cholestyramine on renal function / A. V. Kshirsagar, D. A. Shoham, H. Bang [et al.] // Am. J. Kidney Dis. – 2005. – Vol. 46. – P. 812-819.
The effect of statins on urinary albumin excretion and glomerular filtration rate: results from both a randomized clinical trial and an observational cohort study / J. Atthobari, A.H. Brantsma, R. T. Gansevoort [et al.]// Nephrol. Dial. Transplant. – 2006. – Vol. 21. – P. 3106-3116.
The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study / V. G. Athyros, D. P. Mikhailidis, A. A. Papageorgiou [et al.] // J. Clin. Pathol. – 2004. – Vol. 57. – P. 728-734.
The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomized placebo-controlled trial / C. Baigent, M. J. Landray, C. Reith [et al.] // Lancet. – 2011. – Vol. 377. – P. 2181–2192.
The safety of rosuvastatin as used in common clinical practice: a postmarketing analysis / A. A. Alsheikh- Ali, M. S. Ambrose, J. T. Kuvin, R. H. Karas // Circulation. – 2005. – Vol. 111. – P. 3051-3057.
Treatment with atorvastatin to the National Cholesterol Educational Program goal versus «usual» care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart- disease Evaluation (GREACE) study / V. G. Athyros, A. A. Papageorgiou, B. R. Mercouris [et al.] // Curr. Med. Res. Opin. – 2002. – Vol. 18. – P. 220-228.
Vaziri N. D. Dyslipidemia of chronic renal failure: the nature, mechanisms, and potential consequences / N. D. Vaziri // Am. J. Physiol. Renal. Physiol. – 2006. – Vol. 290. – P. 262-272.
Zoccali C. Novel cardiovascular risk factors in endstage renal disease / C. Zoccali, F. Mallamaci, G. Tripepi // J. Am. Soc. Nephrol. – 2004. – Vol. 15 (Suppl. 1). – P. 77-80.
